Smith Kim Connelly, Armitige Lisa, Wanger Audrey
The University of Texas-Houston Medical School, Community General Pediatrics Division, UT-Houston Kid's Place and Lyndon B Johnson Hospital, 6431 Fannin, MSB 3.150A, Houston, TX 77030, USA.
Expert Rev Anti Infect Ther. 2003 Oct;1(3):483-91. doi: 10.1586/14787210.1.3.483.
Tuberculosis remains the leading cause of death worldwide from a single infectious organism. Approximately 32% of the world's population is infected and an estimated two million people die annually from this treatable disease. Over the past 50 years, with medical treatment and standard public health practices, tuberculosis diminished in developed countries and resulted in a loss of interest and funding for research in improving diagnostic and treatment options. In developing countries, efforts including BCG vaccination have failed to control tuberculosis and the disease continues to spread as the world becomes more globalized. At the same time, multidrug resistant tuberculosis has emerged, challenging even the most advance treatment centers. Better diagnostic techniques, control measures and treatment options are desperately needed but advances require worldwide commitment to battle this age-old disease.
结核病仍然是全球由单一感染源导致死亡的首要原因。全球约32%的人口受到感染,估计每年有200万人死于这种可治疗的疾病。在过去50年里,随着医学治疗和标准公共卫生措施的实施,结核病在发达国家有所减少,导致对改善诊断和治疗方法的研究兴趣和资金投入减少。在发展中国家,包括卡介苗接种在内的努力未能控制结核病,随着世界日益全球化,这种疾病仍在继续传播。与此同时,耐多药结核病已经出现,甚至对最先进的治疗中心也构成了挑战。迫切需要更好的诊断技术、控制措施和治疗方法,但要取得进展需要全球共同致力于抗击这种古老的疾病。